Visteon Corp SEC Filings

Visteon Corporation (VC) filed a Form 144 reporting a proposed sale of 4,350 shares of common stock through Merrill Lynch (100 Campus Drive, Florham Park, NJ) with an approximate aggregate market value of $522,482.00. The filing lists 27,276,339 shares outstanding and an approximate sale date of 08/22/2025 on the NYSE. The securities were acquired in open-market purchases: 1,150 shares on 12/04/2012 and 3,200 shares on 06/13/2014, with full payment made at acquisition. The filer reports no securities sold in the past three months and includes the standard representation that the signer is not aware of undisclosed material adverse information.

Francis M. Scricco, a director of Visteon Corporation (VC), reported two open-market stock sales on 08/19/2025. He sold 3,842 shares at $121.78 and 200 shares at $122.025. After the first sale he beneficially owned 7,342 shares and after the second sale he beneficially owned 7,142. The Form 4 was signed on behalf of Mr. Scricco by Visteon's secretary on 08/21/2025.

Visteon Corporation (VC) filed a Form 144 notifying a proposed sale of 4,042 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $492,284.14, scheduled approximately for 08/19/2025 on NASDAQ. The notice reports total shares outstanding of 27,276,339. The shares originated from restricted stock vesting: 1,850 shares vested 06/08/2024, 1,189 vested 06/23/2023, and 1,003 vested 06/10/2022, each received as compensation. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.

Robert R. Vallance, Senior Vice President of Visteon Corporation (VC), reported a sale of 2,000 shares of the company's common stock on 08/13/2025 at a price of $120 per share. After the transaction, he beneficially owned 18,838 shares directly. The filing states the trades were executed under a Rule 10b5-1 trading plan that Vallance adopted on March 5, 2025. The Form 4 was signed on behalf of the reporting person on 08/14/2025. The report identifies Vallance as an officer (Senior Vice President) and was filed as an individual Form 4.

Visteon Corporation received a Schedule 13G/A (Amendment No. 2) disclosing that American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research beneficially own 2,222,551 shares of common stock, representing 8.2% of the class. The cover pages report sole voting power of 2,173,962 shares and sole dispositive power of 2,222,551 shares. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The position is reported as of 06/30/2025, the filing is signed 08/14/2025, and an exhibit records consent to the joint filing.

VISTEON CORPORATION insider disclosure reports a planned sale of 2,000 common shares through Fidelity Brokerage Services, with an aggregate market value of $240,000 and an approximate sale date of 08/13/2025. The notice lists 27,276,339 shares outstanding and identifies NASDAQ as the exchange.

The filing shows the securities to be sold were acquired as restricted stock vesting on 01/11/2021 (862 shares) and 02/15/2023 (1,138 shares), with payment characterized as compensation. It also discloses recent sales by the same person: 4,000 shares on 06/05/2025 (gross proceeds $329,840) and 2,000 shares on 07/02/2025 (gross proceeds $200,300).

By signing the notice, the seller represents they do not possess any undisclosed material adverse information. Broker details are recorded as Fidelity Brokerage Services LLC.

Victory Capital Management, Inc. filed Amendment No. 1 to a Schedule 13G disclosing beneficial ownership of 1,044,633 shares of Visteon Corp common stock, representing 3.83% of the class. The filing reports 995,979 shares as sole voting power and 1,044,633 shares as sole dispositive power, with the event date listed as 06/30/2025 and the statement signed on 08/08/2025.

The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control. No group affiliations, acquisitions, or other material transactions are disclosed in this amendment.

Visteon Corp (VC) Form 4: SVP & Chief Legal Officer Brett D. Pynnonen reported selling 1,200 common shares on 08/01/2025 in two open-market transactions at $109.86 and $109.85 per share, for proceeds of roughly $132k. Following the sales, his direct beneficial ownership fell from 12,967 to 11,767 shares.

No derivative transactions were reported and no Rule 10b5-1 plan box was indicated. The filing reflects routine insider activity with no accompanying narrative or material company developments.

Visteon Corp. (VC) has filed a Form 144 indicating an insider’s intent to sell up to 1,200 common shares through Fidelity Brokerage on or after 01 Aug 2025. The proposed sale is valued at $131,829, based on the filing’s reference price, and represents roughly 0.004% of the 27.28 million shares outstanding. The shares originated from restricted-stock vesting on 15 Feb 2023 and were received as compensation; no shares have been sold by this filer in the prior three months.

• No material adverse information is claimed by the seller, as affirmed in the signature section.
• The notice does not amend earnings guidance, announce operational events, or affect capital structure; its sole purpose is to comply with Rule 144 disclosure for a routine, small-scale disposition.

Given the limited size relative to float, market impact should be minimal, though investors often monitor insider activity as a sentiment indicator.